Aytu BioPharma, Inc. (NASDAQ:AYTU – Get Free Report)’s share price passed below its 200-day moving average during trading on Tuesday . The stock has a 200-day moving average of $2.36 and traded as low as $1.40. Aytu BioPharma shares last traded at $1.44, with a volume of 12,010 shares changing hands.
Aytu BioPharma Trading Up 2.5 %
The stock has a fifty day moving average of $1.82 and a two-hundred day moving average of $2.36. The company has a market capitalization of $8.82 million, a PE ratio of -1.17 and a beta of -1.40. The company has a current ratio of 0.99, a quick ratio of 0.80 and a debt-to-equity ratio of 0.35.
Aytu BioPharma (NASDAQ:AYTU – Get Free Report) last posted its quarterly earnings results on Thursday, September 26th. The company reported ($0.82) EPS for the quarter, missing the consensus estimate of ($0.45) by ($0.37). Aytu BioPharma had a negative return on equity of 21.89% and a negative net margin of 8.28%. The business had revenue of $17.98 million for the quarter.
Institutional Trading of Aytu BioPharma
Aytu BioPharma Company Profile
Aytu Biopharma, Inc, a commercial-stage pharmaceutical company, focuses on commercializing novel therapeutics and consumer healthcare products the United States and internationally. The company operates through two segments: Rx segment and Consumer Health segment. The Rx segment offers prescription products for the treatment of attention deficit hyperactivity disorder (ADHD), including Adzenys XR-ODT for patients from six years and older, and Cotempla XR-ODT for patients from six to seventeen years old.
Further Reading
- Five stocks we like better than Aytu BioPharma
- Do ETFs Pay Dividends? What You Need to Know
- AppLovin Insiders Sell Shares: Stock Price Indicated Higher
- Best Stocks Under $10.00
- Broadcom’s Stellar Outlook Sparks Hopes for a Semi Sector Rally
- Investing In Preferred Stock vs. Common Stock
- Salesforce’s Clear Path to $400 and Beyond
Receive News & Ratings for Aytu BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aytu BioPharma and related companies with MarketBeat.com's FREE daily email newsletter.